EMEA-000032-PIP01-07-M04
Key facts
| Invented name |
Menveo
|
| Active substance |
Meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) Meningococcal group C oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM) Meningococcal group W-135 oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenW-CRM) Meningococcal group Y oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenY-CRM)
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/93/2011
|
| PIP number |
EMEA-000032-PIP01-07-M04
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Meningococcal meningitis
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
GSK Vaccines S.r.l.
Tel. +1 438 899 8201 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000032-PIP01-07-M04
|
| Compliance opinion date |
25/05/2011
|
| Compliance outcome |
positive
|